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ot All Randomized
rials Are Equal*
. Lance Gould, MD, FACC
ouston, Texas
he study by Beanlands et al. (1) in this issue of the Journal
s a multicenter, randomized trial in 430 patients with
oronary artery disease (CAD) and left ventricular ejection
raction 35% to determine whether a management strat-
gy that included F-18-fluorodeoxyglucose (FDG) positron
mission tomography (PET) imaging to guide revascular-
zation improved clinical outcomes compared with standard
are where FDG PET was not available. On the basis of
trict statistical analysis, the results show that PET FDG
maging for guiding revascularization did not improve
utcomes compared with standard management without
DG PET.
See page 2002
This study adheres to every detail of a randomized trial
xcept for one weakness—25% of the patients with PET-
ndicated revascularization did not have it done. From one
oint of view, the authors are correct in concluding that the
rimary end point, results of PET FDG imaging, had no
enefit compared with standard management for this group
f patients. However, to the extent that 25% of patients
ith PET-indicated revascularization did not have it done,
he study is substantially a trial of whether the deciding
hysician chose to adhere to treatment indicated by PET
DG on the basis of “clinical judgment” and/or bias against
evascularization.
The adherence failures or crossovers reduce the difference
etween control and treated groups that might then become
tatistically insignificant for the number of subjects in the
tudy. In post hoc analysis of the “adherence to PET
ubgroup” of this report, the hazard ratio was 0.62 with p 
.019 for 38% fewer events than the control group, a
aximal difference that is not sufficient to offset the negative
ias of adherence failures in the entire treated group.
Editorials published in the Journal of American College of Cardiology reflect the views
f the authors and do not necessarily represent the views of JACC or the American
ollege of Cardiology.
From The Weatherhead P.E.T. Center for Preventing and Reversing Atheroscle-b
osis, University of Texas Medical School at Houston, Department of Medicine, and
he Memorial Hermann Hospital, Houston, Texas.herefore, adherence failures in the subjects assigned to the
ET group might cause a negative bias against treatment
hat might otherwise be proven effective with a larger study.
In the report by Beanlands et al. (1), failure of random-
zed management might be due to bias against revascular-
zation in Canada, failure to quantify viability sufficiently to
onvince a clinician, or extended clinical circumstances not
onsidered in enrollment criteria. Whatever the reason, it
e-powers the study to a negative or inconclusive outcome
or the initially estimated size. Thus, the experimental
esign failed to anticipate adherence failures with increased
umber of subjects needed to power the study adequately.
In contrast, extensive published data demonstrate that,
or patients with large enough areas of viable ischemic
yocardium to reduce ejection fraction, any of several
easures of viability might serve as an adequate indicator
or revascularization, including single-photon emission
omputed tomography (SPECT) imaging, stress echocar-
iogram, magnetic resonance imaging, post-systolic poten-
iation, and so forth, so that PET imaging is not unique for
his purpose (2). Although negative or inconclusive as a
anagement trial, this report illustrates a basic problem of
omplex clinical management trials in which treatment
uccess or definitive conclusions might depend on physician
r patient bias and/or on asking the right question for the
pecific unique strengths of the imaging technology.
In contrast to this article from Canada, in the U.S., a
arge number of revascularization procedures are done in
table CAD, owing to the opposite bias by physicians doing
hese procedures despite extensive randomized trials dem-
nstrating no reduction in death or infarction, as in the
OURAGE (Clinical Outcomes Utilizing Revasculariza-
ion and Aggressive DruG Evaluation) trial (3), the most
ecent of many reports with the same conclusions. The
EFER (Deferral of PTCA Versus Performance of
TCA) trial (4) further showed that physiologic assessment
f stenosis severity is a valid guide for reducing unnecessary
evascularization procedures with optimal outcomes. The
ff-label use of drug-eluting stents is associated with signif-
cantly higher risk of death or myocardial infarction than
n-label use (5), but off-label use remains widespread.
An interesting survey of invasive cardiologists (6) con-
rms the impression that most stenosis seen at coronary
rteriography will likely be stented regardless of data from
andomized trials to the contrary and concludes, “Although
ardiologists might believe they are benefiting their stable
atients with CAD by performing PCI [percutaneous
oronary intervention], this belief appears to be based on
motional and psychological factors rather than on evidence
f clinical benefit.” Another quote from the article is also
ermane: “The only thing that would really change is if
here had been an imaging study—and it would have
hanged it not by how you responded to the catheterization,
ut by not doing the cath at all” (6).
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Editorial Comment November 13, 2007:2013–15And what imaging study should be performed before the
oronary arteriogram—stress electrocardiogram, SPECT,
r echocardiogram tests? All undoubtedly prevent to some
xtent unnecessary diagnostic arteriograms and associated
tents. However, all are also commonly falsely positive,
eading to unnecessary arteriograms and procedures, or are
alsely negative, which undermines their use for reducing
iagnostic catheterizations. Despite its explosive popularity,
he computed tomography (CT) angiogram with a resolu-
ion limit of 0.625 mm cannot differentiate between a 23%
nd 77% diameter stenosis of a 3-mm coronary artery as
ompared with quantitative arteriography in principle and
n published fact. It thereby serves to prevent some caths by
uling out any CAD in some patients but might lead to
ore unnecessary caths by failing to differentiate severe
rom non-severe stenosis in more patients, because athero-
clerosis is so common. It therefore shares with the other
maging technologies the mixed effects that reinforce the
ominance of invasive procedures without scientific basis.
he lack of reliable precision in all of these imaging
echnologies reinforces a fundamental interventional bias
hat complicates any imaging-management study of CAD.
And thus we return to cardiac PET—what are its unique
trengths? And what is the right question for a trial related
o these issues? Cardiac PET is unique for 2 strengths. The
rst is reliably quantifying relative radionuclide uptake
relative myocardial coronary reserve) without attenuation
rtifacts for small, relative 5% to 10% regional perfusion
ifferences in precise arterial distributions, even for tertiary
mall branches (7–16). The second is quantifying absolute
yocardial perfusion and absolute coronary flow reserve
hat are unique for assessing diffuse disease, multiple steno-
is, mixed diffuse-stenotic or left main disease.
This quantitative capacity provides definitive stand-alone
nformation for identifying early CAD or quantifying se-
erity of more advanced stenotic or diffuse CAD where
mall changes in arterial diameter that cannot be quantified
n an arteriogram have magnified effects on perfusion
mages, because flow is related to the radius raised to the
ourth power. Our current routine determination of absolute
oronary flow and flow reserve in all patients has been an
ye-opener for deciding on invasive procedures, particularly
or identifying severity of stenosis in the best relative
erfused areas of the heart or for identifying the specific
rtery causing angina in complex multi-stenosis disease.
Although cardiac PET is in principle and in careful
ractice the best way of assessing coronary artery disease as
guide to management and invasive procedures (7–16),
ardiac PET can easily be really messed up (17). Cardiac
ET-CT is particularly subject to mis-registration artifacts
ith standard commercial software that fails to address this
roblem (17). This reviewer was the first to define the fluid
ynamics of coronary artery stenosis in vivo, to relate
tenosis severity to perfusion imaging, and to report phar-
acologic stress imaging from planar to PET technology.
ven with training in physics, physiology, and medicine,nd a focused lifelong passion (motivation!) for the task,
ssessing coronary blood flow and myocardial perfusion
maging, reliably as a clinical guide for my management of
AD with minimal invasive procedures and maximal out-
omes has become satisfactory to me only within the past
ew years.
The requirements for the “ultimate imaging test” for
AD were understanding the physiology, developing the
echnology or correcting faulty inadequate technology, and
roving it to myself in clinical practice—and it works as the
ptimal guide to invasive procedures by eliminating unnec-
ssary catheterizations, lowering overall costs, following the
ffects of intense medical treatment, and optimizing out-
omes (7–16). If it did not, this reviewer would shelve PET
nd use whatever other technology was inherently better.
Thus, the “bias” of this reviewer is obvious. However, that
ias is built on confirmed observations over the past 35 years
nd on a near-obsessive criticism of imaging technologies
ompared with physiologic insights needed, particularly for
ardiac PET, which leaves a very small coterie of friendly or
eceptive colleagues sympathetic to this viewpoint. There-
ore the lesson should be clear. The “ultimate imaging” in
AD to balance the powerful invasive bias of cardiology is
ET, a complex imaging technology that is absolutely
efinitive in managing CAD and requires specialized, ex-
erienced, and critical clinical practitioners. It also requires
andomized trials asking the right questions and powered to
ccount for everybody’s imaging biases, including the inva-
ive bias of cardiology with crossovers among randomized
roups.
The balance between invasive and noninvasive manage-
ent of stable CAD is changing on the basis of outcomes of
andomized intervention trials. Cardiac PET, done prop-
rly, potentially offers a definitive quantitative guide to
isease severity, for following its changes, and as the reliable
atekeeper to invasive procedures on the basis of substantial
cientific published data, but needs better-designed ran-
omized trials.
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